Innoveren Scientific Inc (IVRN)

[ProfitChaser]

Added a bunch at .03 today. Today could be bottom at .027

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174037717

[TrendTrade2016]

THERE ARE A TONNE OF COMPANIES THAT SELL THIS SHIT....GOOD SKIN STARTS FROM THE INSIDE...JUST USE RETINOL ON THE OUTSIDE!!!

[ProfitChaser]

Thanks and I agree. Looks very promissing.

[ANTI-BAGHOLDER]

510(k) requires demonstration of substantial equivalence to another legally U.S. marketed device. Substantial equivalence means that the new device is as safe and effective as the predicate. the information submitted to FDA demonstrates that the device is as safe and effective as the legally marketed device.

If they can keep dilution down there may be some big upside here

[splintered sunlight]

Sure sounds like it - thanks

[threewheeler]

insiders took .25 PPS so interesting down here 4 sure Item 3.02 Unregistered Sales of Equity Securities.



Pursuant to the Purchase Agreement, the Company sold an aggregate of 400,000 shares of common stock and 400,000 warrants to purchase shares of Common Stock exercisable at $0.50 per share for gross proceeds of $100,000. All of the shares and warrants described in this Current Report on Form 8-K are being offered and issued to an accredited investor in reliance upon exemptions from the registration requirements under Section 4(a)(2) under the Securities Act of 1933, as amended (“Securities Act”), and Rule 506 of Regulation D promulgated thereunder.

Item 5.02, Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers;



On February 23, 2024, the Company issued to certain executive officers an aggregate of 186,048 shares of common stock in lieu of accrued salary at a rate of $0.25 per share for amounts owed and an aggregate of 213,952 shares for payment of directors’ fees owed.. In addition, the Company converted a promissory note in the amount of $43,091 owed to the Company’s Chief Executive Officer, Michael Yurkowsky, into the private placement in exchange for 172,364 shares of common stock and 172,364 warrants which is the same price paid by the accredited investor..

[ProfitChaser]

Looks like it is worth a shot down here . Grabbed a few just incase.

[threewheeler]

IVRN over 300k traded on tiny 1.1m floater, could see dollars this week

[ANTI-BAGHOLDER]

To bad dilution still on going

[ANTI-BAGHOLDER]

Really nice news on a 1milly floater.

[threewheeler]

yeap news tiny MC SS IVRN Innoveren Scientific Announces 510(k) Submission for SkinDisc(TM) Lite

First Commercial Product Submission from Company's Robust Regenerative Medicine-Based Pipeline

CINCINNATI, OH / ACCESSWIRE / March 6, 2024 / Innoveren Scientific Inc. (OTCQB:IVRN) ("Innoveren" or the "Company"), a life science company focused on becoming a leading biotech incubator, announced today that it has submitted a 510(k) premarket filing to the U.S. Federal Food and Drug Administration (FDA) for its SkinDiscTM Lite product.

SkinDiscTM Lite provides an active and protein-rich cellular matrix that is essential for structural support and cellular attachment during the wound-healing process that can be administered in an outpatient setting. The product maintains complete wound contact and depth fill during the healing process, resulting in rapid growth of the host tissue. SkinDiscTM Lite utilizes autologous platelet-rich plasma (PRP) and platelet poor plasma concentrate, from the patient's own body, helping to mitigate any potential rejection of the product.

"The FDA submission for SkinDiscTM Lite represents a significant milestone for Innoveren Scientific in our journey to advance our new medical technologies in areas of unmet need across multiple indications," said Michael Yurkowsky, Innoveren Scientific's Chief Executive Officer. "With the use of PRP, which already has predicates in wound care cleared by the FDA, we are hopeful we will also receive clearance for SkinDiscTM Lite, allowing us to continue to advance our pipeline and submit a 510(k) submission for SkinDiscTM Ultra in the coming quarters."

Innoveren Scientific is prepared to submit a second 510(k) De Novo submission for SkinDiscTM Ultra should clearance be received for SkinDiscTM Lite. SkinDiscTM Ultra is an operating room-only product for limb salvage that utilizes bone marrow aspirate (BMA).

The Company is also making progress on advancing its BreatheEasy product, a medical device that helps patients struggling with chronic obstructive pulmonary disease (COPD), as well as other closely related diseases such as chronic bronchitis and emphysema. The Company is on track for a 510(k) De Novo submission later this year once additional clinical work has been completed.

About Innoveren Scientific Inc.

Innoveren Scientific Inc., formerly known as H-CYTE, Inc. is a life science and biotech incubator company, focused on advancing new technologies in areas of unmet need across multiple indications, with the ultimate goal of improving patient lives. The company invests in and fosters innovative technologies that are supported by a strong scientific foundation, which have relatively short timelines and low costs to achieve meaningful value inflection points. For more information about Innoveren, please visit www.InnoverenScientific.com. IVRN Security Details
Share Structure
Market Cap Market Cap
85,289
03/05/2024
Authorized Shares
500,000,000
03/04/2024
Outstanding Shares
2,584,518
03/04/2024
Restricted
1,279,698
03/04/2024
Unrestricted
1,304,820
03/04/2024
Held at DTC
1,120,229
03/04/2024

[ANTI-BAGHOLDER]

Nice news out.

https://www.otcmarkets.com/filing/html?id=17345823&guid=x8d-kqtMGq-FJth#ex99-1_htm

[ANTI-BAGHOLDER]

Well, if the PPS was higher this wouldn’t have caught my eye.

[splintered sunlight]

And unfortunately a very small stock price...

[ANTI-BAGHOLDER]

Me too. Still a very small share structure

[splintered sunlight]

Totally forgot about this one.

Perhaps I'll take a look over the weekend.

Thanks

[ANTI-BAGHOLDER]

Reading through the investor presentation they put out yesterday:

https://www.otcmarkets.com/filing/html?id=17137173&guid=SVJ-kqOqQlcjJth

[Renee]

H-CYTE Inc., HCYT, changed to Innoveren Scientific Inc., IVRN:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

[splintered sunlight]

Now bid at .67 offered at 1.05.

What a difference a day makes.....

[wilson9]

1.37 is high.....today

[wilson9]

time to load ....it seems very bullish in few days

[splintered sunlight]

We have a wild one here......

[makinezmoney]

$HCYTD: Now at 3.95


Watching for another entry



GO $HCYTD

[Renee]

HCYT: one for 1,000 reverse split. **pps closed at .02

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

[a surfer]

Maybe?

[JackAskSlap]

Might bite..

[a surfer]

Where did you go brother? It's about to get really fun here!

[a surfer]

On January 13, 2022, the board of directors of H-Cyte, Inc. (the “Company”) appointed Richard Rosenblum and Matthew Anderer as new directors of the Company, effective January 17, 2022.



Mr. Rosenblum (62) is a business veteran and entrepreneur in the areas of the financial services, capital markets, healthcare, technology and real estate. His experience ranges from serving as managing director at several investment merchant banks to heading companies as a C-suite executive. He also sits on the boards of public and private healthcare, life sciences and technology-sector companies.



Mr. Rosenblum is currently President, CFO and Board Member of Innovative Payment Solutions, Inc., a California-based FinTech company focused on building a 21st century universal digital payment and money remittance platform. As the founder of Harborview Capital Advisors, LLC, Mr. Rosenblum leads a team of strategic advisors in the areas of capital formation, merchant banking and management consulting, and has raised more than $250 million in capital funding for companies. Since founding it over 20 years ago, Mr. Rosenblum has served as manager and director of Harborview Property Management LLC, raising over $100 million while managing domestic and international commercial and multi-family real estate assets. From 2008 to 2014, Mr. Rosenblum was Director, President and Executive Chairman of Alliqua Biomedical Inc. (NASDAQ: ALQA), a leader in hydrogel manufacturing technology in the wound care sector.



Mr. Rosenblum received his B.A. in Finance & Accounting from the State University of New York at Buffalo in 1981, graduating summa cum laude.



Mr. Rosenblum will receive $5,000 a month as compensation from the Company for his service as a director.



Mr. Anderer (55) started his career in the United States Air Force as a fast jet and special operations pilot and instructor before taking operational and staff officer roles with Special Operations Command and NATO. He has commanded worldwide airlift capability of the highest posts within the White House and from a technology perspective, he has directed a range of high-profile, high-value acquisition projects. Mr. Anderer was the Director of the US Air Force leadership and citizenship development program for 220,000 cadets before taking command of the busiest air mobility group in the world, responsible for support to destinations world-wide. Among other contingency crisis operations in this capacity, Matt played a crucial role establishing robust, resilient, and repeatable processes to prevent the potential spread of the Ebola Virus for aircraft, cargo and passengers that transited sub-Saharan West Africa. He is currently the training systems Country Integration Lead for Lockheed Martin’s F-35 International customers, a position that he has held since prior to 2017.


Most recently, Mr. Anderer was also a member of the Board for Deverra Theraputics, a clinical stage cell therapy company headquartered in Seattle. He is a graduate of Villanova University, Air Command and Staff College, Naval Staff College and the Geneva Center for Security Policy.



Mr. Anderer will receive $5,000 a month as compensation from the Company for his service as a director.



The board of directors of the Company has affirmatively determined that both Mr. Rosenblum and Mr. Anderer meet the applicable standards for independent directors under Rule 10A-3 of the Securities Exchange Act of 1934.



There is no arrangement or understanding between either Mr. Rosenblum or Mr. Anderer and any other persons pursuant to which either Mr. Rosenblum or Mr. Anderer was elected as a director of the Company. There are no family relationships between either Mr. Rosenblum or Mr. Anderer and any of the Company’s officers or directors. Other than as described herein, there are no other transactions to which the Company or any of its subsidiaries is a party in which either Mr. Rosenblum or Mr. Anderer has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

[a surfer]

Great week here...chart looks really enticing!

[a surfer]

100 share paint job...lol true price .07 Happy New Year!

[a surfer]

Happening nicely! Another 30% plus today!

[a surfer]

Getting ready. Loaded the 3's

[ALERTS100%to10000%GAIN]

HCYT will break crazyy huge

[ALERTS100%to10000%GAIN]

HCYT~~.0498,LOAD ALL YOU CAN,soon will TRADE NASDAQ,life opp.here,,https://centersforrespiratoryhealth.com/bronchiectasis/

[ALERTS100%to10000%GAIN]

HCYT~~H-CYTE Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory Health
Press Release | 09/08/2021
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders, today announced the launch of its newly-named ‘Centers for Respiratory Health’.

Effective immediately, the Company’s “Lung Health Institute” facilities will begin operating under the new name. The change is evolutionary and represents a commitment to data-driven, real-world evidence, along with the need to more accurately capture the broadening scope of the work the H-CYTE clinical development team and its medical professionals accomplish at its Centers.

H-CYTE Chief Executive Officer Robert Greif stated, “We have a new management team, new scientific developments, new supportive shareholders, and clinically relevant, real world data. The name ‘Centers for Respiratory Health’ represents the company’s strategic intent to provide the highest quality, patient-centric, evidence-driven care possible.” Greif added, “Our adjunctive therapy for patients who are already maximizing their maintenance medications for lung disorders, has the potential to drive improvement in lung health for our patients. This next generation therapy brings a new option for patients, pulmonologists and healthcare providers where few choices exist today."

Dr. Tanya Rhodes, Chief Technology Officer for H-CYTE, stated, “We are very excited about the name change to ‘Centers for Respiratory Health’ as it reflects our ongoing commitment to demonstrate the science behind our technology and the positive clinical outcomes we are observing. The field of regenerative medicine is moving at a very fast pace, and our goal is to be at the forefront, providing quality evidence-based care to the patients we serve.”

H-CYTE recently announced the results and publication of two, real world, observational studies supporting the efficacy of its innovative autologous treatment in improving lung health. Both studies resulted in statistically significant improvement(s) in pulmonary function at 3 months after just one treatment.* These improvements were seen out to 12 months in the Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy study. Additionally, statistically significant Quality of Life improvements at 3, 6 and 12 months were reported in both studies. Based on these outcomes, the Company is currently planning a multi-center randomized, double-blind, head-to-head comparison trial involving H-CYTE’s innovative PRP-PBMC therapy, to be conducted by independent pulmonologists across the US.

H-CYTE has a nationwide network of Centers for Respiratory Health. Its mission is to deliver regionally-based, patient-focused, scientifically-backed respiratory care for those with lung disorders.

To learn more about the Centers for Respiratory Health and PRP-PBMC therapy, please visit www.CentersforRespiratoryHealth.com.

*Each patient is different, and results may vary. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to suggest diagnosis, treatment, cure, or prevention of any disease.

About H-CYTE, Inc.

H-CYTE is a medical biosciences company focused in the field of regenerative medicine. H-CYTE’s mission is to become a leader in next-generation, cellular therapeutics for the treatment of chronic health conditions, with the ultimate goal of improving patient lives. For more information about H-CYTE, please visit www.HCYTE.com.

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While H-CYTE believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those outlined in H-CYTE’s filings with the SEC, including but not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. H-CYTE expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACTS

H-CYTE Investor Relations
Jason Assad
[e-mail]
678-570-6791



https://centersforrespiratoryhealth.com/contact/

Contact Us
866-638-4776

[e-mail]

Nashville Location:
2001 Mallory Ln STE 302,
Franklin, TN 37067

Scottsdale Location:
8377 E Hartford Dr STE 120,
Scottsdale, AZ 85255

Tampa Location:
201 E Kennedy Blvd STE 425,
Tampa, FL 33602



https://centersforrespiratoryhealth.com/contact/

[ALERTS100%to10000%GAIN]

HCYT~~.0498,multi dollars going https://centersforrespiratoryhealth.com/treatments/cellular-therapy/

[ALERTS100%to10000%GAIN]

HCYT~~.0462,going back NASDAQ,

H CYTE : Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory Health
09/08/2021 | 08:01am EDT
share with twitter
share with LinkedIn
share with facebook
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders, today announced the launch of its newly-named ‘Centers for Respiratory Health’.

Effective immediately, the Company’s “Lung Health Institute” facilities will begin operating under the new name. The change is evolutionary and represents a commitment to data-driven, real-world evidence, along with the need to more accurately capture the broadening scope of the work the H-CYTE clinical development team and its medical professionals accomplish at its Centers.

H-CYTE Chief Executive Officer Robert Greif stated, “We have a new management team, new scientific developments, new supportive shareholders, and clinically relevant, real world data. The name ‘Centers for Respiratory Health’ represents the company’s strategic intent to provide the highest quality, patient-centric, evidence-driven care possible.” Greif added, “Our adjunctive therapy for patients who are already maximizing their maintenance medications for lung disorders, has the potential to drive improvement in lung health for our patients. This next generation therapy brings a new option for patients, pulmonologists and healthcare providers where few choices exist today."

Dr. Tanya Rhodes, Chief Technology Officer for H-CYTE, stated, “We are very excited about the name change to ‘Centers for Respiratory Health’ as it reflects our ongoing commitment to demonstrate the science behind our technology and the positive clinical outcomes we are observing. The field of regenerative medicine is moving at a very fast pace, and our goal is to be at the forefront, providing quality evidence-based care to the patients we serve.”

H-CYTE recently announced the results and publication of two, real world, observational studies supporting the efficacy of its innovative autologous treatment in improving lung health. Both studies resulted in statistically significant improvement(s) in pulmonary function at 3 months after just one treatment.* These improvements were seen out to 12 months in the Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy study. Additionally, statistically significant Quality of Life improvements at 3, 6 and 12 months were reported in both studies. Based on these outcomes, the Company is currently planning a multi-center randomized, double-blind, head-to-head comparison trial involving H-CYTE’s innovative PRP-PBMC therapy, to be conducted by independent pulmonologists across the US.

H-CYTE has a nationwide network of Centers for Respiratory Health. Its mission is to deliver regionally-based, patient-focused, scientifically-backed respiratory care for those with lung disorders.

To learn more about the Centers for Respiratory Health and PRP-PBMC therapy, please visit www.CentersforRespiratoryHealth.com.

*Each patient is different, and results may vary. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to suggest diagnosis, treatment, cure, or prevention of any disease.

About H-CYTE, Inc.

H-CYTE is a medical biosciences company focused in the field of regenerative medicine. H-CYTE’s mission is to become a leader in next-generation, cellular therapeutics for the treatment of chronic health conditions, with the ultimate goal of improving patient lives. For more information about H-CYTE, please visit www.HCYTE.com.

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While H-CYTE believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those outlined in H-CYTE’s filings with the SEC, including but not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. H-CYTE expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACTS

H-CYTE Investor Relations
Jason Assad
[e-mail]
678-570-6791




Primary Logo
Source: H-CYTE, Inc.
2021 GlobeNewswire, Inc., source Press Releases

and hugee here,,read closely,

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166143539

[Laster]

Another one of your horrible calls.
I think you are losing you touch a little.
I guess most have learned and are now selling into your pumps.
JMO.
Lol.

[ALL-IN888]

.074 LOL $$$

[retireat40]

Good luck with that

[ALL-IN888]

You are not ready to retire yet!!! Loaded all I can today from .065

[retireat40]

Pumped it to death yesterday and today you disappear? Ok then...

[GlefdarLivermore]

I got out at a huge loss today because of this Washington Post article:

https://www.washingtonpost.com/national/health-science/clinic-pitches-unproven-treatments-to-desperate-patients-with-tips-on-raising-the-cash/2019/12/01/fe94cfcc-d3c6-11e8-8c22-fa2ef74bd6d6_story.html

Also this article:

https://ipscell.com/2021/03/fact-check-lung-health-institute-cell-therapies-for-lung-disease/

These are in the top several Google results for "Lung Health Institute." It seems very possible that Wagner being in the stock will make it pump more in the future but I don't want to hold it since I think the company is a scam. GLTA

[Laster]

Never invest in ALLIN888 pumps.
He is the worst trader on OTC.
You will lose every time.
JMO.
Dead cat bounce here?

[makinezmoney]

$HCYT: Lets go...... i'm in with 300k shares now at 0.085


You know how I roll.


Lets make some DINERO !!!!!!!!!!!!!!






GO $HCYT

[retireat40]

Any thoughts for today??

[GlefdarLivermore]

To clarify, Wagner is the majority controlling owner (60%) through
FWHC BRIDGE, LLC which he is the sole manager of. So I think as long as he holds $8m in this and retains majority ownership, maybe he is not going to let the shareholders get too badly screwed over the medium to long term.

[GlefdarLivermore]

Also, I will add that Wagner doesn't seem to invest that often, these are the only filings for him that I see:

https://www.sec.gov/edgar/browse/?CIK=0001066152

The others were in 1998 and 2006.

[GlefdarLivermore]

I found the filing detailing Todd Wagner's investment: https://docoh.com/filing/1591165/0001066152-21-000003/4

It looks like he owns over $8m as a 10% owner and hasn't sold any since acquiring the shares in Q3 2020:

https://docoh.com/company/1591165/HCYT/insider-ownership-history


Based on this maybe an FDA application is going to be an upcoming catalyst. At least eventually.

[chongo0919]

Stock reached .99 cents back in February with much less volume. 7 cents is just over 100% where it was yesterday. With this float and it being an OTCQB stock this is truly a gift. That’s why I grabbed mid 6s and 7s at the end. Any news, any updates this shoots up like nothing. You could see it how it moves how thin this is. Profit taking and old bag holders from the .99 cents top wanted out which is why it didn’t get the natural bounce

I’m all in for a bounce tomorrow but I don’t see it going back to 0.03 cents so I’m holding until they decide to pop it again! Learn how to play the OTC, not many floats like this, secure them when you see them